NEWS
BioSpace I Clene’s Nanocrystal ALS Treatment Bounces Back with Positive Data

Despite missing the initial mark, Clene Inc.’s gold nanocrystal therapy for ALS still shows promise. Thursday, the company shared new results from an exploratory analysis showing CNM-Au8 delayed disease progression across key areas for patients. In October 2022, Clene reported that CNM-Au8 did not meet the primary endpoint of slope of change in the HEALEY ALS trial based on the adjusted […]

NeurologyLive I CNM-Au8 Demonstrates Significant Survival Benefit in HEALEY-ALS Interim Analysis

Newly announced 6-month findings from the HEALEY-ALS Platform trial, the first of its kind for amyotrophic lateral sclerosis (ALS), showed that treatment with CNM-Au8 (Clene Nanomedicine) was tolerable, with several meaningful delays in clinical worsening and increased survival benefit.1 CNM-Au8 is an oral suspension of gold nanocrystals developed to restore neuronal health and function by […]

BioSpace I Biopharma Execs Adopt Creative Mindset at BIO CEO

As biopharma executives sought funding last week at the BIO CEO & Investor Conference, the strategic mindset could be summed up in three words: flexibility, creativity and concession. Seeking a Series C Salt Lake City-based Halia Therapeutics is working to close a $50 million Series C round to drive its lead asset, an NLRP3 inflammasome […]